Five Prime cuts 41 jobs, days be­fore pre­sent­ing da­ta at AS­CO meet­ing of GI can­cers

Things have not been the same at can­cer-fo­cused drug de­vel­op­er Five Prime Ther­a­peu­tics $FPRX since late 2017, when its Bris­tol-My­ers $BMY part­nered drug cabi­ral­izum­ab in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER